REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results
REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (œSoleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...